Golden Helix Featured in Numerous Publications 2020

         January 12, 2021

Golden Helix continues to innovate and grow, and due to this, we have been garnering attention and praise. We are thrilled to share with you some of the accolades and interest from numerous publications from the last six months. Talking points ranged from diagnosing and tracking Covid-19 infections leveraging NGS to new workflows, interpreting and reporting on copy number variants to numerous awards given to our company.

We extend our gratitude for the recognition and will continue to provide quality innovation in the Next-Gen sequencing space.

Diagnosing and Tracking COVID-19 Infections Leveraging Next-Gen SequencingThe Journal of Precision Medicine

July 8, 2020 | The COVID-19 pandemic is reaching historic proportions. We are dealing with an infectious disease that is caused by a novel coronavirus we discovered just a few months ago. Since then, it has brought healthcare systems to the brink, it altered how we work, it changed how we socialize, and it impacted the world economy in a major way.

While a global response has been mobilized to defeat the virus, there are currently no good solutions available. The current goal is to reach a sufficiently high level of immunization in the global population and to develop treatment options. In the meantime, we have to be efficient in diagnosing infections, isolating COVID-19 cases, and studying this virus by understanding its subtypes, epidemiology, routes of transmission, and clinical manifestation. In this article, we summarize our current understanding of COVID-19 and the virus SARS-Cov-2 causing it. Most of the papers we reference were published since the beginning of this year. The body of knowledge is quickly expanding and evolving. Next-Generation Sequencing (NGS) can deliver significant insights into this process. This article outlines how NGS… Read more »

2020 Inc. Magazine Award

August 12, 2020 | Golden Helix, Inc. Claims Position on Acclaimed Inc. 5000 List of Fastest-Growing Private Companies for Second Year Running

Golden Helix has secured its reputation as a global leader in Next-Generation Sequencing solutions for over two decades. Today, we have been included in the esteemed Inc. 5000 list of rapidly growing American companies. Out of the 6 million businesses in the United States, Golden Helix has been honored with a spot on the annual list for the 2nd consecutive year. Read more »

Insight Success AwardThe 10 Most Innovative Pharma and Life Sciences Service Providers 2019

November 6, 2020 | Golden Helix’s main goal is to empower its end-users to perform high-end analytics work. This is achieved by producing software that gives the power of analysis to researchers, supporting them through their analysis, and providing them with genomic services when the need arises. Golden Helix takes pride in itself for creating software tools that are integrated and robust, but more importantly user-friendly and intuitive. The tools are specifically created in order to empower biologists, clinicians, and other researchers to easily perform complex analyses and visualizations, eliminating the need to rely exclusively on bioinformatic experts or cobble together difficult to use, incompatible freeware. This way researchers can completely focus on their research instead of learning to be a programmer or waiting in line for bioinformaticians. The organizations’ support team is motivated by one mission … Read more »

Montana High Tech Business Alliance Montana Biotech Companies to Watch 2020

November 18, 2020 | Since 2017, Golden Helix has seen 110% growth. The Bozeman-based venture was listed on Inc. 5000’s List of Fastest-Growing Companies for the second consecutive year this August and secured the Global Health and Pharma Award during the 2020 Biotechnology Awards.

Golden Helix’s software offers integrated and automated data reporting used to diagnose and research diseases by matching them to a patient’s genetic makeup.

The software platforms, which have been cited in over 1,300 peer-reviewed publications, are used for pharmaceutical research, agricultural genomics, education, human genetic research, and laboratory testing.

Golden Helix programs can be used to automate the bioinformatics process for COVID-19 and more rapidly turnaround diagnosis data. Golden Helix was recently published in the Journal of Precision Medicine for their work diagnosing and tracking coronavirus infections through next-generation Read more »

Best Genomic Data Analysis Software SpecialistsUSA Global Health & Pharma

December 24, 2020 | Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world’s top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, Read more »

Golden Helix’s Recent Release for a New Workflow for Interpreting and Reporting Copy Number Variants in Concordance with the Recently Updated ACMG Guidelines:  IntroductionThe Journal of Precision Medicine

December 28, 2020 | A copy number variation (CNV) is a type of structural variation in which a large section of the genome is either duplicated or deleted. CNVs account for much of the variation between human genomes, and they are associated with a wide range of disorders. As more disorders associated with CNVs are identified, and as NextGen sequencing is more widely utilized in the clinical setting, tools supporting rapid, accurate, and cost-effective identification and interpretation of CNVs are needed.

Recently, the American College of Medical Genetics and Genomics (ACMG) has developed a new set of CNV interpretation guidelines in collaboration with the Clinical Genome Resource (ClinGen) project,1 analogous to the guidelines currently in place for small variants. In the time since the release of these guidelines, the Golden Helix team has developed a new automated workflow that enables Read more »

We hope you enjoyed this Recent Feature Round-Up! If you are interested in reading a few more pieces on Golden Helix, check out our Press Page! Feel free to check out some of our other blogs that always contain important news and updates for the next-gen sequencing community.

Leave a Reply

Your email address will not be published. Required fields are marked *